Display options
Share it on

JIMD Rep. 2017;35:1-5. doi: 10.1007/8904_2016_16. Epub 2016 Nov 18.

Cerebrotendinous Xanthomatosis Presenting with Infantile Spasms and Intellectual Disability.

JIMD reports

Austin Larson, James D Weisfeld-Adams, Tim A Benke, Penelope E Bonnen

Affiliations

  1. Department of Pediatrics, Section of Genetics, University of Colorado School of Medicine, Aurora, CO, USA. [email protected].
  2. Children's Hospital Colorado, Mail Stop 153, 13123 E 16th Ave, Aurora, CO, 80045, USA. [email protected].
  3. Department of Pediatrics, Section of Genetics, University of Colorado School of Medicine, Aurora, CO, USA.
  4. Departments of Pediatrics, Pharmacology, Neurology and Otolaryngology, University of Colorado School of Medicine, Aurora, CO, USA.
  5. Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA. [email protected].

PMID: 27858369 PMCID: PMC5585103 DOI: 10.1007/8904_2016_16

Abstract

Cerebrotendinous xanthomatosis (CTX) is an inborn error of metabolism leading to progressive multisystem disease. Symptoms often begin in the first decade of life with chronic diarrhea, cataracts, developmental delay, intellectual disability, and cerebellar or pyramidal dysfunction. Later manifestations include tendon xanthomas, polyneuropathy, and abnormal neuroimaging. Pathogenic biallelic variants in CYP27A1 leading to compromised function of sterol 27-hydroxylase result in accumulation of detectable toxic intermediates of bile acid synthesis rendering both genetic and biochemical testing effective diagnostic tools. Effective treatment with chenodeoxycholic acid is available, making early diagnosis critical for patient care. Here we report a new patient with CTX and describe the early signs of disease in this patient. Initial symptoms included infantile spasms, which have not previously been reported in CTX. Developmental delay, mild intellectual disability with measured cognitive decline in childhood, was also observed. These clinical signs do not traditionally compel testing for CTX, and we highlight the need to consider this rare but treatable disorder among the differential diagnosis of children with similar clinical presentation. Increased awareness of early signs of CTX is important for improving time to diagnosis for this patient population.

Keywords: Cataracts; Cerebrotendinous xanthomatosis; Developmental delay; Infantile spasms; Intellectual disability

References

  1. Pediatrics. 2009 Jan;123(1):143-7 - PubMed
  2. J Lipid Res. 2007 May;48(5):1167-74 - PubMed
  3. J Lipid Res. 1994 Mar;35(3):478-83 - PubMed
  4. Epilepsy Behav. 2012 Jul;24(3):380-1 - PubMed
  5. Clin Neuropharmacol. 2013 May-Jun;36(3):78-83 - PubMed
  6. J Inherit Metab Dis. 2014 May;37(3):421-9 - PubMed
  7. Radiology. 2000 Dec;217(3):869-76 - PubMed
  8. Brain. 2000 May;123 ( Pt 5):908-19 - PubMed
  9. Metabolism. 2007 Sep;56(9):1248-55 - PubMed
  10. J Inherit Metab Dis. 2002 Oct;25(6):501-13 - PubMed
  11. Eur J Pediatr. 2016 Jan;175(1):143-6 - PubMed
  12. Am J Ophthalmol. 1995 Nov;120(5):597-604 - PubMed
  13. Mol Genet Metab. 2015 Dec;116(4):298-304 - PubMed
  14. Eur J Hum Genet. 2011 Dec;19(12):1238-45 - PubMed
  15. Hum Mol Genet. 2014 Sep 15;23(18):4846-58 - PubMed
  16. Am J Med Sci. 2012 Apr;343(4):332-3 - PubMed
  17. Eur J Pediatr. 1998 Apr;157(4):313-6 - PubMed
  18. J Inherit Metab Dis. 2016 Jan;39(1):75-83 - PubMed
  19. Orphanet J Rare Dis. 2016 Apr 16;11:41 - PubMed

Publication Types

Grant support